nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—Subdural haematoma—Riluzole—amyotrophic lateral sclerosis	0.117	0.118	CcSEcCtD
Rivaroxaban—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0441	0.0446	CcSEcCtD
Rivaroxaban—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.043	0.0435	CcSEcCtD
Rivaroxaban—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.033	0.0334	CcSEcCtD
Rivaroxaban—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.0304	0.0307	CcSEcCtD
Rivaroxaban—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0297	0.03	CcSEcCtD
Rivaroxaban—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.0258	0.0261	CcSEcCtD
Rivaroxaban—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.0221	0.0223	CcSEcCtD
Rivaroxaban—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.0203	0.0205	CcSEcCtD
Rivaroxaban—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.0177	0.0179	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0177	0.0179	CcSEcCtD
Rivaroxaban—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.0149	0.0151	CcSEcCtD
Rivaroxaban—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.0137	0.0138	CcSEcCtD
Rivaroxaban—Infestation—Riluzole—amyotrophic lateral sclerosis	0.0137	0.0138	CcSEcCtD
Rivaroxaban—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.0133	0.0135	CcSEcCtD
Rivaroxaban—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.0133	0.0134	CcSEcCtD
Rivaroxaban—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.013	0.0132	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.0129	0.0131	CcSEcCtD
Rivaroxaban—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.0129	0.013	CcSEcCtD
Rivaroxaban—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.0128	0.013	CcSEcCtD
Rivaroxaban—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.0127	0.0129	CcSEcCtD
Rivaroxaban—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.0123	0.0125	CcSEcCtD
Rivaroxaban—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.0123	0.0124	CcSEcCtD
Rivaroxaban—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0123	0.0124	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.0121	0.0122	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.0121	0.0122	CcSEcCtD
Rivaroxaban—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.012	0.0122	CcSEcCtD
Rivaroxaban—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.0116	0.0117	CcSEcCtD
Rivaroxaban—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.0115	0.0116	CcSEcCtD
Rivaroxaban—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.0114	0.0115	CcSEcCtD
Rivaroxaban—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0113	CcSEcCtD
Rivaroxaban—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0112	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0111	0.0112	CcSEcCtD
Rivaroxaban—Back pain—Riluzole—amyotrophic lateral sclerosis	0.0103	0.0104	CcSEcCtD
Rivaroxaban—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.0103	0.0104	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.0099	0.01	CcSEcCtD
Rivaroxaban—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00987	0.00998	CcSEcCtD
Rivaroxaban—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00975	0.00987	CcSEcCtD
Rivaroxaban—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00963	0.00974	CcSEcCtD
Rivaroxaban—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00957	0.00968	CcSEcCtD
Rivaroxaban—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00938	0.00949	CcSEcCtD
Rivaroxaban—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00909	0.00919	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00903	0.00913	CcSEcCtD
Rivaroxaban—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00898	0.00908	CcSEcCtD
Rivaroxaban—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00889	0.00899	CcSEcCtD
Rivaroxaban—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00871	0.00881	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00871	0.00881	CcSEcCtD
Rivaroxaban—Infection—Riluzole—amyotrophic lateral sclerosis	0.00866	0.00875	CcSEcCtD
Rivaroxaban—Shock—Riluzole—amyotrophic lateral sclerosis	0.00857	0.00867	CcSEcCtD
Rivaroxaban—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00854	0.00864	CcSEcCtD
Rivaroxaban—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0085	0.0086	CcSEcCtD
Rivaroxaban—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00846	0.00856	CcSEcCtD
Rivaroxaban—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00814	0.00823	CcSEcCtD
Rivaroxaban—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00777	0.00786	CcSEcCtD
Rivaroxaban—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00767	0.00776	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00752	0.00761	CcSEcCtD
Rivaroxaban—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00751	0.0076	CcSEcCtD
Rivaroxaban—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00745	0.00754	CcSEcCtD
Rivaroxaban—Pain—Riluzole—amyotrophic lateral sclerosis	0.00745	0.00754	CcSEcCtD
Rivaroxaban—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00718	0.00726	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00712	0.00721	CcSEcCtD
Rivaroxaban—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00692	0.007	CcSEcCtD
Rivaroxaban—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00689	0.00697	CcSEcCtD
Rivaroxaban—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00642	0.00649	CcSEcCtD
Rivaroxaban—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00625	0.00632	CcSEcCtD
Rivaroxaban—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00616	0.00623	CcSEcCtD
Rivaroxaban—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00596	0.00603	CcSEcCtD
Rivaroxaban—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00576	0.00583	CcSEcCtD
Rivaroxaban—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00554	0.0056	CcSEcCtD
Rivaroxaban—Rash—Riluzole—amyotrophic lateral sclerosis	0.00549	0.00556	CcSEcCtD
Rivaroxaban—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00549	0.00555	CcSEcCtD
Rivaroxaban—Headache—Riluzole—amyotrophic lateral sclerosis	0.00546	0.00552	CcSEcCtD
Rivaroxaban—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00518	0.00523	CcSEcCtD
Rivaroxaban—CYP2J2—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.0018	0.159	CbGpPWpGaD
Rivaroxaban—F10—Complement and Coagulation Cascades—C5AR1—amyotrophic lateral sclerosis	0.000617	0.0548	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—CD40LG—amyotrophic lateral sclerosis	0.000538	0.0477	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—C3—amyotrophic lateral sclerosis	0.000475	0.0422	CbGpPWpGaD
Rivaroxaban—F10—Post-translational protein modification—PIGW—amyotrophic lateral sclerosis	0.000441	0.0392	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000342	0.0304	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00031	0.0275	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—IGFALS—amyotrophic lateral sclerosis	0.000276	0.0245	CbGpPWpGaD
Rivaroxaban—F10—Complement and Coagulation Cascades—C3—amyotrophic lateral sclerosis	0.000269	0.0239	CbGpPWpGaD
Rivaroxaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00026	0.0231	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000239	0.0212	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000218	0.0194	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—PIGW—amyotrophic lateral sclerosis	0.000209	0.0186	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000203	0.018	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000202	0.0179	CbGpPWpGaD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000193	0.0171	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—XRN2—amyotrophic lateral sclerosis	0.000192	0.017	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000191	0.0169	CbGpPWpGaD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00016	0.0142	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	0.000159	0.0141	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.00014	0.0124	CbGpPWpGaD
Rivaroxaban—CYP2J2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000139	0.0123	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000137	0.0121	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000131	0.0116	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	0.000131	0.0116	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.00013	0.0115	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000126	0.0112	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	0.00011	0.00977	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000106	0.00943	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000106	0.00943	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	9.91e-05	0.0088	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—VAPA—amyotrophic lateral sclerosis	9.72e-05	0.00863	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	9.36e-05	0.0083	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.04e-05	0.00802	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	8.93e-05	0.00793	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—FIG4—amyotrophic lateral sclerosis	8.5e-05	0.00754	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	8.01e-05	0.00711	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—DAO—amyotrophic lateral sclerosis	7.68e-05	0.00682	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	6.91e-05	0.00613	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	6.53e-05	0.00579	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	6.42e-05	0.0057	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—SOD1—amyotrophic lateral sclerosis	6.09e-05	0.0054	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PLB1—amyotrophic lateral sclerosis	5.82e-05	0.00517	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	5.46e-05	0.00485	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSR—amyotrophic lateral sclerosis	5.37e-05	0.00477	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	5.17e-05	0.00458	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	4.89e-05	0.00434	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	4.56e-05	0.00405	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	4.49e-05	0.00399	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CHAT—amyotrophic lateral sclerosis	4.41e-05	0.00392	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	4.36e-05	0.00387	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	4.15e-05	0.00369	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	4.1e-05	0.00364	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.03e-05	0.00357	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4e-05	0.00355	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.94e-05	0.0035	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	3.74e-05	0.00332	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—IGF1—amyotrophic lateral sclerosis	3.71e-05	0.0033	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	3.17e-05	0.00281	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	3.06e-05	0.00272	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	3.06e-05	0.00272	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	2.92e-05	0.00259	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	2.8e-05	0.00249	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.76e-05	0.00245	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	2.7e-05	0.0024	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	2.67e-05	0.00237	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	2.65e-05	0.00235	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.6e-05	0.00231	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	2.55e-05	0.00226	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	2.45e-05	0.00217	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.43e-05	0.00215	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	2.41e-05	0.00214	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.37e-05	0.00211	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	2.31e-05	0.00205	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	2.31e-05	0.00205	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	2.29e-05	0.00204	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	2.21e-05	0.00197	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.18e-05	0.00193	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	2.11e-05	0.00188	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.05e-05	0.00182	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.05e-05	0.00182	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.97e-05	0.00174	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.86e-05	0.00165	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	1.85e-05	0.00164	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.83e-05	0.00163	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—amyotrophic lateral sclerosis	1.83e-05	0.00163	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.83e-05	0.00162	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—APOE—amyotrophic lateral sclerosis	1.79e-05	0.00159	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	1.73e-05	0.00154	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	1.68e-05	0.00149	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	1.67e-05	0.00148	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	1.55e-05	0.00137	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	1.44e-05	0.00128	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	1.42e-05	0.00126	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	1.42e-05	0.00126	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.33e-05	0.00118	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.3e-05	0.00116	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	1.27e-05	0.00113	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.27e-05	0.00112	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.23e-05	0.00109	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.21e-05	0.00107	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	1.17e-05	0.00104	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.14e-05	0.00101	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	1.13e-05	0.001	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.03e-05	0.000914	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	9.6e-06	0.000852	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	8.55e-06	0.000759	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	7.8e-06	0.000693	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	7.2e-06	0.000639	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.84e-06	0.000607	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.28e-06	0.000558	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	5.91e-06	0.000525	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	5.17e-06	0.000459	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.16e-06	0.000458	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.74e-06	0.000421	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	3.9e-06	0.000346	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.54e-06	0.000314	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.18e-06	0.000282	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.92e-06	0.000259	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.67e-06	0.000237	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	2.4e-06	0.000213	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.65e-06	0.000146	CbGpPWpGaD
